Sculptor Capital LP Buys New Shares in Penumbra, Inc. $PEN

Sculptor Capital LP purchased a new position in Penumbra, Inc. (NYSE:PEN) during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 57,000 shares of the company’s stock, valued at approximately $18,717,000.

Several other institutional investors also recently modified their holdings of the stock. Larson Financial Group LLC lifted its position in shares of Penumbra by 4,100.0% during the 4th quarter. Larson Financial Group LLC now owns 84 shares of the company’s stock valued at $26,000 after acquiring an additional 82 shares during the last quarter. CIBC Private Wealth Group LLC grew its holdings in shares of Penumbra by 2,700.0% in the 4th quarter. CIBC Private Wealth Group LLC now owns 84 shares of the company’s stock worth $26,000 after acquiring an additional 81 shares during the last quarter. Motiv8 Investments LLC acquired a new stake in shares of Penumbra during the fourth quarter worth $27,000. Morse Asset Management Inc acquired a new stake in shares of Penumbra during the fourth quarter worth $39,000. Finally, Farther Finance Advisors LLC raised its position in shares of Penumbra by 27.1% during the fourth quarter. Farther Finance Advisors LLC now owns 178 shares of the company’s stock worth $55,000 after purchasing an additional 38 shares during the period. Institutional investors own 88.88% of the company’s stock.

Penumbra Stock Down 0.0%

PEN stock opened at $318.60 on Monday. The company has a 50 day moving average of $319.45 and a two-hundred day moving average of $330.02. The company has a market cap of $12.53 billion, a price-to-earnings ratio of 73.41, a PEG ratio of 1.98 and a beta of 0.70. Penumbra, Inc. has a 12-month low of $221.26 and a 12-month high of $362.41. The company has a quick ratio of 3.95, a current ratio of 6.02 and a debt-to-equity ratio of 0.01.

Penumbra (NYSE:PEN) last posted its quarterly earnings results on Wednesday, May 6th. The company reported $0.82 EPS for the quarter, missing the consensus estimate of $1.06 by ($0.24). Penumbra had a net margin of 11.76% and a return on equity of 10.87%. The company had revenue of $374.76 million for the quarter, compared to analysts’ expectations of $370.47 million. During the same quarter in the prior year, the firm earned $0.83 earnings per share. The company’s revenue was up 15.6% on a year-over-year basis. On average, equities analysts anticipate that Penumbra, Inc. will post 5.02 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of research firms recently weighed in on PEN. Citigroup decreased their price target on Penumbra from $374.00 to $350.00 and set a “neutral” rating for the company in a research report on Thursday, May 7th. Zacks Research downgraded Penumbra from a “hold” rating to a “strong sell” rating in a report on Monday, June 29th. Royal Bank Of Canada reaffirmed a “sector perform” rating and set a $374.00 price objective on shares of Penumbra in a research note on Thursday, June 11th. Weiss Ratings reiterated a “hold (c)” rating on shares of Penumbra in a report on Friday, July 17th. Finally, Wall Street Zen raised shares of Penumbra to a “hold” rating in a research report on Saturday, May 9th. Three equities research analysts have rated the stock with a Buy rating, fourteen have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $360.33.

About Penumbra

Penumbra, Inc is a global healthcare company specializing in the development and manufacture of innovative medical devices that address neurovascular and peripheral vascular conditions. The company focuses on products designed to improve patient outcomes in acute ischemic stroke, aneurysm treatment and peripheral thrombectomy. Penumbra’s technologies are used by interventional neuroradiologists, neurosurgeons and interventional cardiologists in hospitals and clinics around the world.

At the core of Penumbra’s portfolio is its mechanical thrombectomy platform, which includes aspiration catheters and accessory devices engineered to remove blood clots in acute stroke cases.